A synthetic analog of human<unk>  with proline substitutions in positions 25, 26 and 29, or pramlintide (brand name Symlin), was approved in 2005 for adult use in patients with both diabetes mellitus type 1 and diabetes mellitus type 2. Insulin and pramlintide, injected separately but both before a meal, work together to control the post-prandial glucose excursion.<unk>  is degraded in part by insulin-degrading enzyme.
Amylin
Lactitol
Trephine
Thiamylal
Diatrizoate
Sodium azide
Acemannan
Kaurenoic acid